iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
May 02 2022 - 8:00AM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer
of next-generation biopharmaceuticals and pioneer of the
sustainable
FastPharming Manufacturing
System, announced today that it will present a poster at the 18th
Annual Protein & Antibody Engineering Summit (PEGS) Boston
Conference & Expo, May 2-5.
Rachel Jordan, PhD, a senior product manager at
iBio, will present the poster (#P061), titled "Plant-Made
Antibodies Show Superior Glycosylation Homogeneity While Retaining
Pharmacokinetic Properties," which highlights:
- The production of a single uniform G0 glycosylation pattern,
lacking fucose and xylose, of NISTmAb and rituximab when compared
to Chinese Hamster Ovary (CHO) cell culture produced antibodies,
which contain more heterogeneous glycosylation patterns.
- Comparability of in vivo rodent pharmacokinetic profiles for
NISTmAb and rituximab produced using mammalian cell culture and the
FastPharming System.
- How rapid, scalable transient expression in plants of
high-quality mAbs for in vivo studies can significantly shorten the
time to achieve in vivo proof-of-concept.
More information about producing consistent,
high-quality antibodies in the FastPharming System
may be accessed in a whitepaper here.
About iBio, Inc.
iBio is a developer of next-generation
biopharmaceuticals and a pioneer in sustainable, plant-based
biologics manufacturing. Its
FastPharming® System combines
vertical farming, automated hydroponics, and novel glycosylation
technologies to rapidly deliver high-quality monoclonal antibodies,
vaccines, bioinks and other proteins. iBio is developing
proprietary biopharmaceuticals for the treatment of cancers, as
well as fibrotic and infectious diseases. The Company’s
wholly-owned subsidiary, iBio CDMO LLC, provides
FastPharming Contract Development and
Manufacturing Services along with Glycaneering
Development Services™ for advanced recombinant protein design. For
more information, visit www.ibioinc.com.
Forward-Looking Statements
Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "predict," "forecast," "project," "plan," "intend" or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. These
forward-looking statements are based upon current estimates and
assumptions and include statements regarding the
FastPharming Manufacturing System; the ability to
produce mAbs containing more heterogeneous glycosylation patterns
as compared to other manufacturing systems; and producing mAbs that
are comparable in vivo rodent pharmacokinetic profile as compared
to other manufacturing systems. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are subject to various
risks and uncertainties, many of which are difficult to predict
that could cause actual results to differ materially from current
expectations and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the Company’s ability to build a scalable
manufacturing process using the Company’s
FastPharming System; and the other factors
discussed in the Company’s filings with the SEC including the
Company’s Annual Report on Form 10-K for the year ended June 30,
2021 and the Company’s subsequent filings with the SEC on Forms
10-Q and 8-K. The information in this release is provided only as
of the date of this release, and the Company undertakes no
obligation to update any forward-looking statements contained in
this release on account of new information, future events, or
otherwise, except as required by law.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024